PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

• Published in: Blood Vol. 134; no. Supplement_1; p. 4222
• Main Authors: Gbyli, Rana, Song, Yuanbin, Liu, Wei, Gao, Yimeng, Chandhok, Namrata S, Fu, Xiaoying, Wang, Xiaman, Patel, Amisha, Sundaram, Ranjini, Tebaldi, Toma, Biancon, Giulia, Ardasheva, Anastasia, Qin, Ashley, Sadykov, Mukhtar, Mamillapalli, Padmavathi, Flavell, Richard, Prebet, Thomas, Bindra, Ranjit, Halene, Stephanie
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 13.11.2019

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are heterogeneous clonal disorders. Isocitrate dehydrogenase-1 and -2 (IDH1/2) mutations are detected in ~20% of AML and ~5% of MDS, in which they confer gain of a neomorphic function that leads to the production of (R)-2-hydroxyglutar...